Healthcare Technology Company Becomes Organization’s Provider of Enterprise Solutions for Pharmacy Benefits Administration Read More »

As healthcare costs continue to rise in 2020, Valpak, a leader in local print and digital marketing, recently announced a new way to help their customers save on prescription drugs: ValpakRx. Read More »

MakoRx's new disruptive pharmacy subscription model provides access to over 300 medications for free Read More »

Best in Class Ingredients from Diamond Dust to Caviar, Retinol to The Most Bioavailable Oil-Soluble Vitamin C Read More »

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biotechnology company specializing in the development of novel treatments for brain tumors, today announced that Anthem Biosciences of Bangalore, India (Anthem) has completed a pilot run of the recrystallization of the Reata Pharmaceuticals, Inc. API (Reata). Read More »

PharmaMar and Jazz signed an exclusive license agreement on 19 December 2019 for lurbinectedin in the United States Read More »

DisposeRx, Inc., manufacturer of the market leading at-home medication disposal solution, has in place a network of more than 1,000 pharmacies in New Jersey ready to meet the requirements of new legislation signed into law today. Read More »

Loopback Analytics, a leading provider of data-driven solutions for hospital and health systems, announced today they are working with UF Health Jacksonville to help advance specialty pharmacy services. Read More »

Partnership designed to make essential compounded sterile products for CADD® infusion pumps more widely available Read More »

Luye Pharma Group has announced submission of a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for LY03005, a new chemical drug for the treatment of major depressive disorder. It is also the second U.S. FDA NDA submission in the central nervous system (CNS) filed by the company. Read More »

In response to the announcement of Trump administration proposals to allow importation of certain prescription drugs, the American Pharmacists Association (APhA) expressed its overwhelming concerns for patient safety. Read More »

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) announced that it has completed its open label trial evaluating 8 mg twice-daily compared to 16 mg once-daily dosing of CTP-543 in patients with moderate-to-severe alopecia areata. Read More »

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). Read More »

e5 Pharma, LLC., today announced the U.S. launch of Diazoxide, USP Oral Suspension, the first generic version of the reference listed drug, Proglycem®. e5 Pharma received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) using the Competitive Generic Therapy (CGT) Pathway. Read More »

Trividia Health, Inc., the largest U.S. manufacturer of store brand products for people with diabetes, and Mellitus Health, Inc., a leading innovator of software for diabetes care professionals who manage insulin therapy, have partnered to develop solutions to help improve diabetes care through pharmacies and pharmacy-based clinics. Read More »

KIRO Fill® will bring greater autonomy to syringe batching of non-hazardous intravenous (IV) medications Read More »

DisposeRx—through its vast network of more than 2,000 pharmacies in Texas—is working to help pharmacists and pharmacies ensure compliance of HB 2088 through the availability of its safe, at-home disposal packets and patient education. Read More »

Nearly 90 percent survival for patients who received REGN-EB3 treatment earlier in the course of their disease; 66.5 percent survival among all patients who received REGN-EB3 Read More »

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic and other major diseases, today jointly announced with Eli Lilly and Company ("Lilly") that the innovative PD-1 inhibitor Tyvyt® (sintilimab injection), co-developed by both companies, is the only PD-1 inhibitor that has been included in the new Catalogue of National Reimbursement Drug List ("NRDL") according to the latest announcement from the National Healthcare Security Administration ("NHSA"). Read More »

In an effort to advocate for the communities and members they serve, Inland Empire Health Plan (IEHP) CEO, Jarrod McNaughton, contributed to the California Pharmacy Carve Out discussion in the MJH Life Sciences publication, Managed Healthcare Executive to explain how it impacts IEHP members, providers and local community. Read More »